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Abstract
Introduction: Mucositis induced by anti-neoplastic drugs is an important, dose-
limiting and costly side-effect of cancer therapy.
Aim: To evaluate the effect of the topical application of S-nitrosoglutathione
(GSNO), a nitric oxide donor, on 5-fluorouracil (5-FU)-induced oral mucositis in
hamsters.
Materials and Methods: Oral mucositis was induced in male hamsters by two
intraperitoneal administrations of 5-FU on the first and second days of the
experiment (60 and 40 mg/kg, respectively) followed by mechanical trauma on the
fourth day. Animals received saline, HPMC or HPMC/GSNO (0.1, 0.5 or 2.0 mM)
1 h prior to the 5-FU injection and twice a day for 10 or 14 days. Samples of cheek
pouches were harvested for: histopathological analysis, TNF-a and IL-1b levels,
immunohistochemical staining for iNOS, TNF-a, IL-1b, Ki67 and TGF-b RII and a
TUNEL assay. The presence and levels of 39 bacterial taxa were analyzed using
the Checkerboard DNA-DNA hybridization method. The profiles of NO released
from the HPMC/GSNO formulations were characterized using chemiluminescence.
Results: The HPMC/GSNO formulations were found to provide sustained release
of NO for more than 4 h at concentration-dependent rates of 14 to 80 nmol/mL/h.
Treatment with HPMC/GSNO (0.5 mM) significantly reduced mucosal damage,
inflammatory alterations and cell death associated with 5-FU-induced oral
mucositis on day 14 but not on day 10. HPMC/GSNO administration also reversed
the inhibitory effect of 5-FU on cell proliferation on day 14. In addition, we observed
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that the chemotherapy significantly increased the levels and/or prevalence of
several bacterial species.
Conclusion: Topical HPMC/GSNO accelerates mucosal recovery, reduces
inflammatory parameters, speeds up re-epithelization and decreases levels of
periodontopathic species in mucosal ulcers.
Introduction
Oral mucositis is considered one of the most common and devastating side effects
of chemotherapy and radiotherapy treatment for cancer. Its prevalence ranges
from between 10% to 100% depending on system cytotoxicity and patient-
associated endogenous variables, therefore representing a significant risk factor for
systemic infection [1–3].Oral mucositis is an epithelial damage characterized by
erythematous, atrophic and ulcerative lesions. Its physiopathology is complex and
has been described by Sonis and colleagues as a sequence of interrelated biological
events comprising initiation, the primary damage response, signaling and
amplification, ulceration, and healing [4].
The more critical phase is the ulcerative phase where bacteria are particularly
important. It is well established that both Gram-negative and Gram-positive
bacteria form a pseudomembrane that invades the submucosa, which is rich in
macrophages, and their cell-wall products (i.e., lipopolysaccharides, lipoteichoic
acid, cell wall antigens, and a-glucans) stimulate those cells to further secrete pro-
inflammatory cytokines, particularly interleukin-1 (IL-1) and tumor necrosis
factor-alpha (TNF-a) [5]. However, thus far, the association between mucositis
and changes in the oral bacterial community is poorly understood. The majority
of the bacterial species present in the oral cavity are harmless commensal bacteria,
and under normal, healthy conditions, they exist in homeostasis in the oral cavity
[6]. In patients with malignancies, this homeostasis between host defense and
commensal bacterial has been thought to be disturbed by the cancer itself, by
cancer-related secondary immunodeficiency, or by prophylactic antibacterial
agents. This disruption in homeostasis may contribute to the oral mucosa tissue
breakdown following chemotherapy [7]. Cytokines have been shown to stimulate
the expression of inducible nitric oxide synthase (iNOS) with consequent
production of nitric oxide (NO), a signaling molecule responsible for several
physiological and pathophysiological actions throughout the human body,
including control of blood flow and modulation of the immune response [8, 9].
Although the chemical structure of NO is simple, its biological effects are indeed
complex. This gas appears to play beneficial and detrimental roles. The
detrimental effects may include a cytotoxic action towards adjacent host tissues,
resulting in pain and tissue lesions. The production of large amounts of NO by
iNOS has been show to play a major role in immune reactions and in many
inflammatory processes including oral mucositis. Our group has demonstrated
S-Nitrosoglutathione and Oral Mucositis
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that treatment of hamsters with iNOS inhibitors reduced lesions found in 5-
fluorouracil (5-FU)-induced oral mucositis significantly, suggesting an important
role of iNOS-mediated NO production in the pathogenesis of oral mucositis
induced by 5-FU [10]. In contrast, beneficial effects may include antimicrobial
activity [11], collagen deposition and keratinocyte proliferation [12–14].
Despite its long history and its impact on patients, there are currently no
effective treatment options to prevent or treat mucositis associated with
chemoradiation therapy for cancer of the head and neck [15]. The goals of
mucositis management are to prevent or reduce the severity of toxicity and to
manage the associated symptoms, which will, in turn, enable the continued
delivery of cancer therapy without interruption or dose reduction and improve
the overall prognosis [16].
S-nitrosoglutathione (GSNO) is a primary s-nitrosothiol with strong
vasodilatory [17] and wound-healing properties [18, 19] that may release NO
spontaneously. It is also capable of transnitrosating cysteine residues of proteins
and exerts a marked microbicidal action [20, 21]. These combined properties of
GSNO, in addition to its miscibility in non-toxic and mucoadhesive hydro-
xypropyl methylcellulose (HPMC; a pharmaceutical vehicle) [22], make HPMC/
GSNO formulations a promising option for investigating the effects of local NO-
donor administration on the course of 5-fluorouracil (5-FU)-induced oral
mucositis, which is the purpose of the present study.
Materials and Methods
Reagents and drugs
Hydroxypropyl methylcellulose (HPMC; Mn 90000), glutathione (GSH), sodium
nitrite (NaNO2), phosphate-buffered saline (PBS) pH 7.4, acetone and hydro-
chloric acid (HCl) were purchased from Sigma (St. Louis, MO, USA). 5-
fluorouracil (5-FU) was purchased from Roche (Rio de Janeiro, Brazil). All
reagents were analytical grade and were used as received. All experiments were
performed using deionized water from a Millipore Milli-Q gradient filtration
system (Billerica, Massachusetts, USA).
S-nitrosoglutathione synthesis
S-nitrosoglutathione (GSNO) was synthesized by reacting GSH with NaNO2 in
equimolar conditions in acidic solution (HCl, pH 2.0) based on a procedure
described elsewhere [23]. Solid, dry GSNO was stored protected from light at
220 C˚ for further use.
Preparation of HPMC/GSNO formulations
Aqueous GSNO solutions (0.10 mM, 0.50 mM and 2.0 mM) were prepared in
PBS pH 7.4. Eight milliliters of each solution was added to separate Falcon tubes
containing 100 mg of HPMC. The mixtures were vortexed until completely
S-Nitrosoglutathione and Oral Mucositis
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homogenous, thus forming viscous transparent HPMC/GSNO formulations. The
falcon tubes were refrigerated for 2 h to assure the complete dissolution of the
polymer. The prepared formulations were used for the in vitro and in vivo
experiments and were always stored back in the refrigerator after use. The
formulations were discarded after 3 days of use. All GSNO solutions and HPMC/
GSNO formulations were protected from light during handling using aluminum
foil.
Real-time NO release from the HPMC/GSNO formulations
The profiles of NO release from the HPMC/GSNO formulations (0.1 mM,
0.5 mM and 2.0 mM) were determined over periods of up to 5 h using a
chemiluminescence NO analyzer (NOA 280i, Sievers Instruments Inc., Boulder,
CO, USA) operated at 37 C˚ with an O2 pressure of 6.0 psig and a N2 pressure of
6.0 Torr. Each replicate of real-time NO release was obtained for a 2-mL volume
of the HPMC/GSNO formulation containing 100 mL of an anti-foaming solution
(provided by Sievers) in the sampling flask of the instrument. Measurements were
performed in triplicate, and the data are expressed as the mean ¡ SEM.
In vivo studies
Animals
Golden hamsters from the Federal University of Ceara´ weighing 140–200 g were
housed in temperature-controlled rooms under 12-hour light-dark cycles, and
they received water and food ad libitum. Surgical procedures and animal
treatments were conducted in accordance with the Guidelines for Institutional
and Animal Care and Use of Federal University of Ceara´, Brazil. All procedures
involving animals were approved by the Federal University of Ceara´ Committee
on the ethical treatment of research animals.
Experimental model of 5-FU-induced oral mucositis
Oral mucositis was induced by two intraperitoneal (i.p.) administrations of 5-FU
on the first and second days of the experiment (60 and 40 mg/kg, respectively)
based on a previously described experimental oral mucositis model [10]. On day
4, under 2.5% tribromoethanol (250 mg/kg, i.p.)-induced anesthesia, the right
cheek pouch mucosa was irritated by superficial scratching to potentiate the oral
mucositis. The scratching comprised dragging the tip of an 18-gauge needle, twice
in a linear manner, across the everted cheek pouch. The animals were euthanized
under anesthesia (2.5% tribromoethanol; 250 mg/kg, i.p.) on the 10th or 14th day
after the initial injection of 5-FU.
Experimental groups
The treated groups were divided into 3 subgroups that differed only in the GSNO
concentration of the topical formulation applied to both cheek pouch mucosas
twice daily: HPMC formulations containing three different concentrations of
GSNO: 0.1 mM (0.1 mM HPMC/GSNO), 0.5 mM (0.5 mM HPMC/GSNO) or
S-Nitrosoglutathione and Oral Mucositis
PLOS ONE | DOI:10.1371/journal.pone.0113378 December 5, 2014 4 / 25
2.0 mM (2.0 mM HPMC/GSNO). All treated animals received 5-FU and
mechanical trauma in the right cheek pouch mucosa. The control animals were
divided into 4 control subgroups: a group of healthy hamsters that received no
treatment (H); hamsters that received only mechanical trauma and topical
application of saline swabs to both cheek pouches twice daily (MT); hamsters that
received 5-FU, mechanical trauma in the right cheek pouch mucosa and topical
application of vehicle to both cheek pouches twice daily (HPMC); and hamsters
that received 5-FU, mechanical trauma in the right cheek pouch mucosa and
topical application of saline to the mucosa of both cheek pouches (Saline). There
were at least 6 animals in each experimental group.
Macroscopic analysis of cheek pouches
For macroscopic analysis, inflammatory aspects such as erythema, erosion,
vasodilatation, epithelial ulcerations and abscesses, were evaluated in a single-
blinded fashion and graded as follows: Score 0, completely healthy cheek pouch
with an absence of erosion or vasodilatation; Score 1: presence of erythema but no
evidence of erosion in the cheek pouch; Score 2: severe erythema, vasodilation and
surface erosion; Score 3: formation of ulcers in one or more faces of the mucosa
that did not affect more than 25% of the surface area of the cheek pouch; severe
erythema and vasodilatation; Score 4: cumulative formation of ulcers in
approximately 50% of the surface area of the cheek pouch; and Score 5: almost
complete ulceration of the cheek pouch mucosa. In these cases, fibrosis makes the
exposure of oral mucosa difficult [24]. Photographs were used for scoring the
lesions.
Histopathological analyses
The specimens were fixed in 10% neutral buffered formalin, dehydrated and
embedded in paraffin. Sections (5 mm thick) were obtained for hematoxylin-eosin
staining (H&E) and were examined by light microscopy (640). Inflammatory cell
infiltration, vasodilatation, presence of hemorrhagic areas, edema, ulcerations and
abscesses were determined in a single-blinded fashion and graded as follows: Score
0: normal epithelium and connective tissue without vasodilatation, absent or
discreet cellular infiltration, an absence of hemorrhagic areas, ulcerations and
abscesses; Score 1: discreet vasodilatation, areas of re-epithelization, discreet
inflammatory infiltration with mononuclear prevalence, an absence of hemor-
rhagic areas, edema, ulcerations and abscesses; Score 2: moderate vasodilatation,
areas of hydropic epithelial degeneration, inflammatory infiltration with
neutrophil prevalence, the presence of hemorrhagic areas, edema and eventual
ulcerations and an absence of abscesses; and Score 3: severe vasodilatation,
inflammatory infiltration with neutrophil prevalence, the presence of hemorrhagic
areas, edema and extensive ulceration and abscesses [10].
Quantification of cytokines by ELISA
Cheek pouch samples were harvested from animals of all groups on the 10th or
14th day after the initial injection of 5-FU for interleukin 1-b (IL-1b; DuoSet
S-Nitrosoglutathione and Oral Mucositis
PLOS ONE | DOI:10.1371/journal.pone.0113378 December 5, 2014 5 / 25
ELISA Development kit, R&D systems, #DY501) and tumor necrosis factor a
(TNF-a; DuoSet ELISA Development kit, R&D systems, #DY510) measurements.
The concentrations of cytokines contained in the samples were measured using an
enzyme-linked immunosorbent assay (ELISA), as described previously [25]. The
results are expressed as pg/ml of IL-1b or TNF-a.
Immunohistochemistry for iNOS, IL-1 b, TNF-a and TGF-b RII
Immunohistochemical staining for iNOS, IL-1b, TNF-a and type II transforming
growth factor beta receptor (TGF-b RII) on day 14 of MO was performed using
the Envision+Dual Link System HRP method using formalin-fixed, paraffin-
embedded tissue sections (4 mm thick) that were mounted on poly-L-lysine-
coated microscope slides. The sections were deparaffinized and rehydrated using
xylene and graded alcohols. After antigen retrieval (retrieval solution from Spring-
ABCAM; 25 min), endogenous peroxidases were blocked (15 min) with hydrogen
peroxide (Hydrogen Peroxide Block, Spring-ABCAM) and washed in phosphate-
buffered saline (PBS). Non-specific proteins were blocked (20 min) with Protein
Block (Spring-ABCAM). Sections were incubated overnight (4 C˚) with polyclonal
goat anti-rabbit primary antibody (anti-iNOS, anti-IL-1b, anti-TNF-a, anti TGF-
b RII or anti-Ki67, (Santa Cruz Biotechnology, #sc8310, sc7884, sc1350, sc17791
and sc7846, respectively) diluted 1:200 in antibody diluent (Dako #S0809). After
washing, the slides were then incubated with Dako labeled polymer (Envision Flex
Dako #K4010) for 30 min. iNOS, IL-1b, TNF-a or TGF-b RII were visualized
using the chromogen 3,39diaminobenzidine (DAB). Negative-control sections
were processed simultaneously as described above but the primary antibody was
replaced with antibody diluent (DAKO), and none showed iNOS, IL-1b, TNF-a
or TGF-b RII immunoreactivity. Slides were counterstained with Harris
hematoxylin, dehydrated in a graded series of ethanol, cleared in xylene and
coverslipped. The DAB-stained cells were counted (10 fields per slide; 61000) for
statistical comparisons.
Cell proliferation and cell death
5-FU-induced cell death was investigated on the 14th day using the terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL)
method (ApopTagR, #S7101, Merck, Millipore). Briefly, after deparaffinizing, the
samples were rehydrated and incubated with 20 mg/mL proteinase K for 15 min at
room temperature. Endogenous peroxidases were blocked by treating with 3% (v/
v) hydrogen peroxide in PBS for 5 min at room temperature. After washing, the
sections were then incubated in a humidified chamber at 37 C˚ for 1 h with TdT
buffer containing TdT enzyme and reaction buffer. Specimens were incubated for
10 min at room temperature with a stop/wash buffer and then incubated in the
humidified chamber for 30 min with anti-digoxigenin peroxidase conjugate at
room temperature. After a series of PBS washes, the slides were covered with
peroxidase substrate for color development and then washed in three changes of
dH2O and counterstained in 0.5% (w/v) methyl green for 10 min. at room
temperature. The TUNEL-positive cells were counted (10 fields per slide; 61000)
S-Nitrosoglutathione and Oral Mucositis
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for statistical comparisons. Cell proliferation was assessed on the 14th day based
on Ki67 immunohistochemistry. Ki67 is a nuclear antigen that is present in
proliferating cells but absent in quiescent cells [26, 27]. Cheek pouches from
control, saline and 0.5 mM HPMC/GSNO groups were immunostained using the
streptavidin-biotin-peroxidase method, as described above. The Ki67-positive
cells were counted (10 fields per slide; 61000) for statistical analysis.
Microbiological assessment
Just prior to euthanasia, a swab was obtained from the oral ulcers to sample the
superficial layer. These samples were submitted to Checkerboard DNA-DNA
hybridization with modifications for analysis of the presence and amount of 39
bacterial taxa (Table 1) [28, 29]. Immediately after swabbing, the samples were
placed in individual Eppendorf tubes containing 150 mL of TE buffer (10 mM
Tris-HCl, 0.1 mM EDTA, pH 7.6) and were lysed by adding 150 mL of 0.5 M
NaOH. The samples were then boiled for 10 min, and the denatured DNA was
neutralized with 800 mL of 5 M ammonium acetate and fixed in individual lanes
to a nylon membrane (#RPN303B, Hybond-N1, GE Healthcare Life Sciences,
Piscataway, NJ, USA) using the Minislot 30 apparatus (#SB-30, Immunetics,
Cambridge, MA, USA). The Miniblotter 45 apparatus (#20930013-1,
Immunetics) was used to hybridize whole genomic DNA probes for the bacterial
taxa. The probes were labeled with digoxigenin (Random Primer Digoxigenin
Labeling Kit, Roche Molecular Systems, Alameda, CA, USA). DNA from serotypes
a and b of Aggregatibacter actinomycetemcomitans (Aa) was pooled in one probe.
Bound probes were detected using anti-digoxigenin phosphatase-conjugated
antibody (#11093274910, Roche Molecular Systems) and fluorescence
(#11681982001, ECF, GE Healthcare Life Sciences) by an image capture system
(Storm 860, Molecular Dynamics, GE Healthcare Life Sciences). Signals captured
on the computer were evaluated visually by comparing with the standards at 105
and 106 cells for each test species. Samples were scored as: 0, not detected; 1,,105
cells; 2, approximately 105 cells; 3, 105–106 cells; 4, approximately 106; and
5,.106 cells. The sensitivity of this assay was adjusted to permit the detection of
104 cells of a given species by adjusting the concentration of each DNA probe.
This procedure was performed to provide the same sensitivity for detecting each
species. Failure to detect a signal was scored as zero; however, it is possible that
counts in the range of 1–1000 were present.
In vitro studies
Cell culture
Oral myofibroblast primary cultures were established from newborn rat (Rattus
norvegicus) oral mucosas. Briefly, samples of jugal mucous were removed and
disinfected in 70% alcoholic solution. The initial fragment was cut into small
pieces using an iris scissors and immersed in 0.2% type II collagenase (Invitrogem
#17101) and Dulbecco’s modified Eagle medium comprising nutrient mixture
F12 (DMEM-F12; GIBCO #12400-24) supplemented with glucose (33 mM),
S-Nitrosoglutathione and Oral Mucositis
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glutamine (2 mM), sodium bicarbonate (3 mM), penicillin/streptomycin
(0.5 mg/mL), fungizone (2.5 mg/mL) and 10% v/v fetal bovine serum (FBS;
Invitrogen #12657-029) at 37 C˚ in a humidified atmosphere containing 5% CO2
and 95% air for 1 h. This mixture was centrifuged for 1 min at 1200 rpm, and the
pellet containing the cells was resuspended in DMEM-F12. Cells were plated on
pre-coated poly-L-lysine plates (5 mg/mL) and the medium was changed every
two days until the cells reached confluence.
Immunocytochemistry
Cultured oral fibroblasts from newborn rats were incubated in a medium
containing GSNO 0.5 mM for 90 min. Cell cultures in a GSNO-free medium were
used as a control. Immunofluorescent staining was performed on whole-mount
preparations of subconfluent cell cultures using a monoclonal antibody specific
for the type of smooth muscle (1:100; monoclonal mouse anti-human smooth
muscle actin clone 1A4I, DAKO #M0851), anti-phalloidin conjugated to
fluorescein (FITC 1:200; SIGMA #P5282) and mouse anti-human Ki67 (1:50;
monoclonal mouse anti-human, NOVOCASTRA #NCL-ki67-MM1). For
immunocytochemical analysis, 26105 cells were plated on coverslips placed in
24-well plates. The cells were fixed with 4% PFA in PBS for 15 min. Fixed cells
Table 1. Bacterial strains used to construct whole genomic DNA probes that were then used for testing hamster buccal epithelial cell samples.
Taxa Strains Taxa Strains
Aggregatibacter actinomycetemcomitans a 43718* Leptotrichia buccalis 14201*
Aggregatibacter actinomycetemcomitans b 29523* Neisseria mucosa 19696*
Actinomyces gerencseriae 23860* Parvimonas micra 33270*
Actinomyces israelli 12102* Prevotella melaninogenica 25845*
Actinomyces odontolyticus 17929* Porphyromonas gingivalis 33277*
Actinomyces naeslundii I 12104* Prevotella intermedia 25611*
Actinomyces oris 43146* Prevotella nigrescens 33563*
Campylobacter rectus 33238* Propionibacterium acnes 11827*
Capnocytophaga gingivalis 33624* Selenomonas noxia 43541*
Capnocytophaga ochracea 33596* Streptococcus anginosus 33397*
Capnocytophaga sputigena 33612* Streptococcus constellatus 27823*
Campylobacter showae 51146* Streptococcus mitis 49456*
Campylobacter concisus 484* Streptococcus oralis 35037*
Eubacterium nodatum 33099* Streptococcus sanguinis 10556*
Eikenella corrodens 23834* Streptococcus gordonii 10558*
Fusobacterium periodonticum 33693* Streptococcus intermedius 27335*
Fusobacterium nucleatum polymorphum 10953* Tannerella forsythia 43037*
Fusobacterium nucleatum vincentii 49256* Treponema denticola B1{
Fusobacterium nucleatum nucleatum 25586* Treponema socranskii D40DR
Gemella morbillorum 27824* Veillonella parvula 10790*
* ATCC (American Type Culture Collection, Rockville, MD);
{The Forsyth Institute, Cambridge, MA.
doi:10.1371/journal.pone.0113378.t001
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were then washed with PBS and incubated with 5% BSA diluted in PBS for
30 min. Cells were incubated with mouse anti-human Ki67 (1:100), anti-
phalloidin and anti-smooth muscle alpha actin antibodies. Cells were incubated
overnight at 4 C˚ with the primary antibodies, then washed with PBS and
incubated with secondary antibodies conjugated to monoclonal Alexa Fluor 488
(donkey anti-goat;1:500; FITC; INVITROGEN) or 546 (goat anti-mouse; 1:500;
rhodamine; INVITROGEN) for 2 h. Cells were then washed with PBS, stained
with DAPI (SIGMA #D9542), washed with PBS and mounted. Negative controls
were performed using non-immune mouse IgG. Cells were imaged using an
epifluorescence microscope (Nikon TE300) and a confocal microscope (Leica
TCS-SP5) equipped with a 636 NA 1.40 oil-immersion objective. Image
processing was performed using CorelDRAW Graphics Suite X5. The Ki67-
positive cells were counted (10 fields/slide; 10006) for statistical comparisons.
Statistical analysis
The data were presented as mean ¡ SEM or as median where appropriate.
Kruskal Wallis and Mann Whitney tests were used to compare means and
medians using Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). The
microbial analyses were carried out using the SPSS program v. 19.0 (IBM,
Armonk, New York, NY, USA). The microbiological data were presented as mean
levels (6105 bacterial cells) of the tested species. The levels of each species were
calculated by transforming the scores 0–5 in counts. Then, mean counts were
computed for each animal (5 per group) and within groups. The mean frequency
(prevalence) of detection of a studied species was also obtained for each group.
Significant differences among groups, for levels and prevalence, were determined
by Kruskal-Wallis and Mann Whitney tests, for comparisons including all groups
or between two groups, respectively. In the in vitro study, each experiment was
performed in three replicates and the results are the means ¡ SD of three
independent experiments. All the values were represented as the means ¡
standard deviation and statistical analysis was performed with the use of the
Mann-Whitney test (control group versus 0.5 mM GSNO treated group). The
significance level was 5% for all analyses.
Results
Profiles of NO release from the HPMC/GSNO formulations
Figure 1A shows that the 0.5 and 2.0 mM HPMC/GSNO formulations released
NO in a concentration-dependent and sustained fashion for 1 h. The level of NO
released from the 0.1 mM HPMC/GSNO formulation was below the detection
limit of the chemiluminescence method.
Figure 1B shows the corresponding integrated NO signals extracted from the
two curves in Figure 1A which represent the total amount of NO released from
these formulations on the same time scale. The rates of NO release shown above
S-Nitrosoglutathione and Oral Mucositis
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the curves in Fig. 1B were obtained by linear regression of the experimental data
(denoted by the straight lines). The total amounts of NO released from the
2.0 mM and 0.5 mM HPMC/GSNO formulations after 1 h were 4% and 3% of
initial GSNO content, respectively.
Complementary measurements of NO release from the 2.0 mM HPMC/GSNO
formulation in a prolonged time showed that it can maintain a constant rate of
NO release for 4 h at 37 C˚ (Figure S1 in File S1). This rate corresponds to a total
amount of 320¡80 nmol of NO released per mL of hydrogel, implying that after
4 h ca. 12% of the initial pool of GSNO in the gel was decomposed. An
extrapolation to longer times allows considering that the biological action of NO
in topical applications is probably maintained over 12 h, although a gradual
decrease in the rate of NO release is expected in this period. Of course, in oral
applications of a hydrogel other important factors must be considered over long
periods, especially the dissolution of the hydrogel by the saliva and its mechanical
removal by the fluid dynamics of the oral cavity. In any case, the desired biological
action can be modulated by establishing the ideal frequency of reapplication of the
hydrogel.
Macroscopic and histopathological analyses of oral mucosa
The i.p. administration of 5-FU followed by mechanical trauma of the cheek
pouch caused significant macroscopic lesions (P,0.05), which were observed on
Figure 1. Real-time NO release profiles of the HPMC/GSNO formulations. (A) Kinetic curves of NO release from the 0.5 mM and 2.0 mM HPMC/GSNO
formulations, measured by chemiluminescence. (B) Integrated NO signals extracted from the curves of Fig. 1A, which indicate the total NO released from
the formulations over the same time-scale. The straight lines denote linear regressions of the experimental data.
doi:10.1371/journal.pone.0113378.g001
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day 10. Compared with the control group of healthy animals (Figure 2a; Table 2)
or animals subjected to mechanical trauma, only 5-FU and mechanical trauma
(Table 2) caused increased erythema, hemorrhage, extensive ulcers and abscesses
(Table 2). These effects of 5-FU at day 10 were not inhibited significantly by
topical application of HPMC/GSNO at any of the concentrations tested (Table 2).
On day 14, treatment with 0.5 mM HPMC/GSNO (Figure 2e; Table 2)
significantly (P,0.05) reduced inflammatory alterations when compared with the
non-treated group subjected to the experimental mucositis (5-FU administration
and mechanical irritation) and that received topical application of HPMC only
(Figures 2c; Table 2).
Histopathology of the cheek pouches of animals subjected to 5-FU-induced oral
mucositis revealed accentuated vasodilatation, intense cellular infiltration with
neutrophil prevalence, hemorrhagic areas, edema, abscesses and extensive ulcers at
day 10, compared with the cheek pouches of healthy hamsters (Table 2) or
hamsters exposed to mechanical trauma only (Table 2). The topical application of
HPMC/GSNO did not significantly inhibit 5-FU-induced inflammatory cell
infiltration, edema, abscesses, hemorrhage or ulceration at day 10 of the
experiment (Table 2). Figure S2 in file S1 illustrates the neutrophil infiltration (by
the quantification of the neutrophils in the cheeh pouch) in the seven
experimental groups on the 14th day. The treatment with 0.5 mM HPMC/GSNO
significantly reduced the number of neutrophils in the cheek pouches as
compared to HPMC group (Figure S2 in File S1). In contrast, we observed an
increased re-epithelization of the cheek pouch of animals treated with topical
applications of 0.5 mM HPMC/GSNO on the 14th day of the experiment
(Figure 2f; Table 2) when compared with the non-treated group (Figure 2d;
Table 2), and no effect of the other concentrations was observed.
Cheek pouch tissue cytokine levels
5-FU significantly (P,0.05) increased cheek pouch tissue levels of TNF-a but not
IL-1b on day 14 (Figures 3A and 3B). The topical application 0.5 mM HPMC/
GSNO but not 0.1 mM or 2.0 mM HPMC/GSNO reduced the 5-FU-induced
increase in TNF-a and restored this parameter to the levels of Healthy or MT
control animals (Figure 3A). No significant differences in IL-1 levels were
observed between experimental groups on day 14 (Figure 3B).
Immunohistochemical staining for iNOS, IL1-b, TNF-a, TGF-b RII
and Ki67
Figure 4 illustrates immunostaining for iNOS, IL-1b, TNF-a and TGF-b RII in
cheek pouches of hamsters subjected to 5-FU-induced oral mucositis (Figures 3c,
3g, 3k and 3o, respectively) on the 14th day of treatment compared with the weak
staining observed in the Healthy control group (Figures. 3b, 3f, 3j, 3n). Local
application of 0.5 mM HPMC/GSNO for 14 days caused a considerable reduction
in both iNOS and TNF-a immunostaining (Figures 3d and 3i, respectively) but
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Figure 2. Macroscopic and microscopic aspects of healthy hamster cheek pouches (a and b) or cheek
pouches from animals subjected to 5-fluorouracil (5-FU)-induced oral mucositis and that received
topical applications of the vehicle HPMC (c and d) or GSNO (0.5 mM) (e and f) observed on day 14. Oral
mucositis was induced by i.p. dministration of 5-fluorouracil followed by mechanical trauma of the cheek
pouch. Animals received topical applications of S-nitrosoglutathione (0.5 mM HPMC/GSNO) or vehicle only
(HPMC) at 1 h prior to 5-FU and every 12 h thereafter for 14 days. Each cheek pouch was everted and
photographed, and samples were removed and processed for hematoxylin and eosin staining (1006
magnification). Details: in Figure 2c, macroscopic edema (arrowhead) and vasodilation (dotted line) are
shown; in Figure 2d, microscopic edema (larger circled) and severe vasodilation (smaller circled) are shown.
Arrow5ulcerations.
doi:10.1371/journal.pone.0113378.g002
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had no effect on IL-1b immunostaining (Figure 4h) when compared with the
untreated group comprising animals subjected to experimental mucositis and that
received saline (Figures 3c and 3k, respectively). In contrast, 0.5 mM HPMC/
GSNO increased TGF-b RII immunostaining in cheek pouch tissue markedly (
Figure 4p) compared with the Saline group (Figure 4o). When the antibodies
were replaced with PBS/BSA 5%, no immunostaining was detected (negative
control; Figures 3a, 3e, 3i and 3m). Figure 5 shows the quantification of cells in
cheek pouches of hamsters subjected to 5-FU-induced oral mucositis that received
Figure 3. TNF-a and IL-1b levels (pg/ml) in the cheek pouches of hamsters subjected to 5-FU-induced oral mucositis on day 14. Oral mucositis was
induced in hamsters by intraperitoneal (i.p.) injection of 5-FU followed by mechanical trauma (MT) of the cheek pouch. Animals received topical applications
of a gel containing S-nitrosoglutathione (0.1, 0.5 and 2.0 mM HPMC/GSNO) 30 min prior to 5-FU and twice daily thereafter for 10 days or 14 days. Control
groups comprised normal animals (N), animals subjected to mechanical trauma (MT) only and animals subjected to 5-FU-induced oral mucositis that
received local application of saline (saline) or vehicle (HPMC). Bars denote the mean¡ standard error of TNF-a and IL-1b levels in six animals per group.
*denotes values significantly different (P,0.05) from the Healthy group; +denotes values significantly different (P,0.05) from the Saline group; #denotes
values significantly different (P,0.05) from the HPMC group. Data were analyzed using the Kruskal Wallis and Mann Whitney tests.
doi:10.1371/journal.pone.0113378.g003
Table 2. Macroscopic and microscopic analysis of cheek pouch tissue of hamsters subjected to 5-FU-induced oral mucositis and treated with topical
applications of S-nitrosoglutathione (0.5 mM), observed on days 10 and 14.
Control and experimental
groups H
MT (10th
day)
MT (14th
day) 5-FU
HPMC (10th
day)
HPMC (14th
day)
Saline (10th
day)
Saline (14th
day)
0.5 mM (10th
day)
0.5 mM (14th
day)
Macroscopic analysis 0(0–0) 3(0–4)* 2(2–4)* 3(2–5)* 3(2–5)* 4(2–5)* 3(2–5)* 4,5(1–5)* 2(1–5)*,*
Microscopic analysis 0(0–0) 2.5(0–3)* 1.5(0–3)* 3(1–3)* 2(1–3)* 2.5(0–3)* 3(2–3)* 3(0–3)* 1(0–3)*,**
Oral mucositis was induced in hamsters by intraperitoneal (i.p.) injection of 5-FU followed by mechanical trauma (MT) of the cheek pouch. Animals received
topical applications of S-nitrosoglutathione (0.5 mM), vehicle (HPMC) or saline 1 h prior to 5-FU and every 12 h thereafter for 10 days. H5healthy group,
i.e., animals without oral mucositis. Data denote the median values (and range) of macroscopic or microscopic scores in six animals per group.
*P,0.05 compared with healthy animals (H group),
**P,0.05 compared with Saline group. Data were analyzed using Kruskal Wallis and Mann Whitney tests.
doi:10.1371/journal.pone.0113378.t002
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daily applications of saline (Saline) or 0.5 mM HPMC/GSNO for 14 days that were
positive for TNF-a (Figure 5A), IL-1b (Figure 5B), iNOS (Figure 6C) or TGF-b
RII (Figure 5D). A significantly greater number of TNF-a-, IL-1b- and iNOS-
positive cells (P,0.05) were observed in cheek pouches of animals subjected to oral
mucositis and that received saline or HPMC when compared with the Healthy
group (Figures 4A, 4B and 4C, respectively). The topical application of 0.5 mM
HPMC/GSNO reduced (P,0.05) the number of iNOS- and TNF-a-positive cells
when compared with both the HPMC and Saline groups; however, the treatment
did not reduce the number of IL-1b-positive cells (Figure 5B). Experimental oral
Figure 4. Representative examples of iNOS (1st row), IL-1b (2nd row), TNF-a (3rd row) and TGF-b RII (4th
row) immunostaining on day 14 in tissues from cheek pouches of hamsters subjected to 5-FU-induced
oral mucositis. Staining was performed using cheek pouches from healthy animals (b, f, j, n) and animals
subjected to 5-FU-induced mucositis that received topical applications of S-nitrosoglutathione (GSNO;
0.5 mM; d, h, l, p) or saline (c, g, k, o). Negative controls were samples of cheek pouches where the primary
antibody was replaced with PBS-BSA (5%); no immunostaining was detected (a, e, i, m). Magnification,
61000.
doi:10.1371/journal.pone.0113378.g004
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mucositis significantly (P,0.05) increased TGF-b RII -positive cells in cheek pouch
tissue compared with the Healthy group. There was also a 2-fold increase (P,0.05)
in the number of TGF-b receptor-II-positive cells in the 0.5 mM HPMC/GSNO
group compared with the HPMC and Saline groups.
Cell proliferation and cell death
The cheek pouches of animals subjected to 5-FU-induced oral mucositis showed a
significant increase (P,0.05) in TUNEL-positive cells on day 14 when compared
Figure 5. Quantification of TNF-a- (A), IL-1b- (B), iNOS- (C) and TGF-b RII - (D) positive cells in cheek pouch tissues of hamsters subjected to 5-FU-
induced oral mucositis, on day 14. Oral mucositis was induced in hamsters by intraperitoneal (i.p.) injection of 5-FU followed by mechanical trauma (MT)
of the cheek pouch. Animals received topical applications of a gel containing 0.5 mM S-nitrosoglutathione (GSNO) 30 min prior to 5-FU and twice daily
thereafter for 10 days or 14 days. Control groups comprised healthy animals (H) and animals subjected to 5-FU-induced oral mucositis that received local
applications of saline (Saline). Cells positive for staining were counted (10 fields per slide, 4006) for statistical comparisons. Bars denote the means ¡
standard errors of positive cells from four slides per group (4 animals per group). *denotes significant differences (P,0.05) compared with the Healthy
group; +denotes a significant difference (P,0.05) compared with the Saline group; #denotes a significant difference (P,0.05) compared with the HPMC
group. Data were analyzed using the Kruskal Wallis and Mann Whitney tests.
doi:10.1371/journal.pone.0113378.g005
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with the Healthy control group. 0.5 mM HPMC/GSNO treatment substantially
(P,0.05) reduced the number of TUNEL-positive cells in cheek pouch tissue
compared with both the HPMC and Saline groups (Figure 6A). Figure 5B
illustrates cell proliferation (based on Ki67 expression) in cheek pouches of
hamsters subjected to oral mucositis. On day 14, a significant decrease in the
number of Ki67-positive cells in the Saline group compared with the Healthy
group was observed. Treatment of animals subjected to 5-FU-induced mucositis
with 0.5 mM HPMC/GSNO for 14 days resulted in a 2-fold increase in Ki67-
positive cells compared with the HPMC and Saline groups.
Microbiological assessment
The prevalence and the mean bacterial levels in the swabs obtained from the oral
ulcers of the animals are presented in Fig. 7. Of all 39 bacterial genomic probes
tested, only 21 and 19 species showed significant differences between groups in
levels and frequency of detection, respectively (p,0.05, Kruskal-Wallis test).
Actinomyces naeslundii I, Streptococcus constellatus, Eubacterium nodatum,
Aggregatibacter actinomycetemcomitans, Treponema socranskii, Streptococcus san-
guinis, Streptococcus oralis, Capnocytophaga ochracea, Actinomyces israelii,
Treponema denticola, Prevotella nigrescens, Campylobacter showae, and
Capnocytophaga gingivalis were not detected in any sample suggesting that they do
not inhabit the oral cavity of hamsters under any circumstances. Conversely,
Streptococcus intermedius, Streptococcus gordonii, Propionibacterium acnes,
Figure 6. Cell death and proliferation in the cheek pouches of hamsters subjected to 5-FU-induced oral mucositis, on day 14. Oral mucositis was
induced in hamsters by intraperitoneal (i.p.) injection of 5-FU followed by mechanical trauma (MT) of the cheek pouch. Animals received topical applications
of a gel containing 0.5 mM S-nitrosoglutathione (GSNO) 30 min prior to 5-FU and twice daily thereafter for 10 days or 14 days. Control groups comprised
healthy animals (H) and animals subjected to 5-FU-induced oral mucositis that received local applications of saline (saline). The TUNEL- and Ki67-positive
cells were counted (10 fields per slide, 4006) for statistical comparisons. Bars denote the means¡ standard errors of stained cells from at four slides per
group (4 animals per group). *denotes a significant difference (P,0.05) compared with the Healthy group; **denotes a significant difference (P,0.05)
compared with the MT group, +denotes a significant difference (P,0.05) compared with the Saline group; #denotes a significant difference (P,0.05)
compared with the HPMC group. Data were analyzed using the Kruskal Wallis and Mann Whitney tests.
doi:10.1371/journal.pone.0113378.g006
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Leptotrichia buccalis, Campylobacter concisus, and Prevotella intermedia were
detected in all samples. Comparisons between Healthy and MT groups showed
similar prevalences of all species analyzed with the exception of Fusobacterium
nucleatum nucleatum, Selenomonas noxia, and Veilonella parvula, which showed a
lower prevalence in the Healthy group (p,0.05). These data suggest that
mechanical trauma of cheek pouch tissue itself may affect the composition of oral
microbiota because the MT group did not undergo 5-FU administration.
However, chemotherapy led to a significant change in the composition of the
microbial community and resulted in a significant increase in the levels and/or
prevalence of several species (Porphyromonas gingivalis, Fusobacterium nucleatum
vicentii, Campylobacter rectus, Parvimonas micra, Actinomyces oris, Fusobacterium
nucleatum polymorphum, Fusobacterium periodonticum, S. gordonii, Tannerella
forsythia, S. noxia, Eikenella corrodens, Gemella morbillorum, L buccalis, and C.
concisus) compared with the MT group and the Healthy group (p,0.05). In
contrast, Actinomyces gerencseriae, Neisseria mucosa, and Prevotella melaninogenica
Figure 7. Oral bacterial species evaluated in mucositis lesions of hamsters. Only species showing significant differences between groups are
displayed. Left panel: mean bacterial counts using log 10; Right panel: frequency of detection, %. * denotes p,0.05 and { p#0.001 between groups using
the Kruskal Wallis test. The number of animals in each group was at least five.
doi:10.1371/journal.pone.0113378.g007
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were present at significantly lower levels in the groups subjected to 5-FU
treatment (0.5 mM HPMC/GSNO, Saline, and HPMC groups) compared with
the MT and H groups (p,0.05).
Comparisons between the 0.5 mM HPMC/GSNO and Saline or HPMC groups
revealed that the prevalence and levels of only two or four species, respectively,
showed significant differences. Levels of P. melaninogenica and Actinomyces
odontolyticus were significantly higher in the Saline and HPMC groups compared
with the 0.5 mM HPMC/GSNO group (p,0.05) suggesting an antibacterial effect
of GSNO.
Immunocytochemistry of oral fibroblast primary culture
Figure 8 shows representative immunostaining for Ki67, a marker of proliferating
cells, in myofibroblasts incubated for 90 min in medium containing GSNO
(0.5 mM) (Figures 8e, 8f, 8g, 8h) or that was GSNO-free (untreated control;
Figures 8a, 8b, 8c and 8d). An increase in the expression of Ki67 was observed in
the cells incubated with GSNO (0.5 mM; Figures 8b and 8d) compared with
untreated cells (Figures 8f and 8h). Figure 9 illustrates fibroblast proliferation
(based on Ki67 expression) in the GSNO-treated cells and the untreated control
cells after 30, 90 and 180 min of incubation. Treatment of cells with GSNO for 90
and 180 min, but not 30 min, resulted in an increase (P,0.05) in Ki67-positive
cells compared with untreated control cells.
Figure 8. Primary cultures of oral fibroblasts from newborn rats incubated for 90 min in medium containing GSNO (a–d) or GSNO-free (e–h). The
cells were immunostained using antibodies against smooth muscle anti-alpha-actin (c, d, g and h) or Ki67 (b, d, f and h), and nuclei were labeled with DAPI
(a, d, e and h). Treatment of cells with 0.5 mM HPMC/GSNO for 90 min increased the expression of Ki67 (f and h) compared with untreated cells (b and d).
Merged images are shown on the right (d and h). Scale bar510 mm.
doi:10.1371/journal.pone.0113378.g008
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Discussion
We demonstrated that the topical application of HPMC/GSNO formulations did
not prevent lesions induced by 5-FU in the oral mucosa of hamsters on the 10th
day of experiment, which corresponds to maximal mucositis in hamsters [30].
However, our results showed that the topical application of 0.5 mM HPMC/
GSNO accelerated the healing process, as observed on the 14th day after initial
administration of 5-FU. This positive effect of HPMC/GSNO on the healing phase
of experimental oral mucositis was associated with reduced mucosa-inflammatory
cell infiltration, decreased TNF-a levels and reduced immunostaining for iNOS
and TNF-a in the cheek pouches of hamsters subjected to 5-FU-induced oral
mucositis. In addition, in both in vivo and in vitro experiments, we also observed a
positive effect of GSNO on cell proliferation based on Ki67 immunostaining. We
did not observe anti-inflammatory or proliferative effects of 0.1 mM HPMC/
GSNO on 5-FU-induced oral mucositis. We speculate that this concentration was
not sufficient to provide effective concentrations of NO in the oral mucosal tissue.
Additionally, under the same conditions, treatment with 2.0 mM HPMC/GSNO
did not show any positive effects on the healing of oral ulcers. Consistent with our
study, it has been demonstrated that high doses of exogenous NO increase clot
formation and reactive tissue and impair collagen organization, which together
contribute to cellular toxicity and delayed wound repair [31]. Our data are
consistent with literature showing that the biological effect of NO is highly
dependent on its concentration [32, 33].
In this respect, it must be noted that the sustained level of NO detected by
chemiluminescence, shown in Figs. 1A and 1B, implies a constant rate of GSNO
decomposition and NO release within the HPMC vehicle. This behavior may be
explained by the bimolecular reaction between two GSNO molecules, based on
Eq. 1:
2GSNO~GS-SGz2NO ð1Þ
Figure 9. Quantification of immunohistochemical staining of oral myofibroblasts using an anti-Ki67
antibody. A robust increase in Ki67-positive cells was observed following treatment with S-nitrosoglutathione
(GSNO; 0.5 mM) for 90 and 180 min. Values denote the means¡ standard deviations. * denotes a significant
difference (P,0.05) compared with untreated cells.
doi:10.1371/journal.pone.0113378.g009
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where the only byproduct, in addition to NO, is oxidized glutathione (GS-SG).
The straight lines in Figure 1B, suggesting a zero-order reaction, are in fact the
result of the small change in GSNO concentration after 1 h of decomposition,
allowing to assume that the GSNO concentration remains approximately constant
during this time period. Thus, the rate of reaction 1 can be expressed as:
r~k’ ð2Þ
where k95k[GSNO]2, k is the second-order rate constant of the reaction and
[GSNO]2 is constant. The increase of only 5.7-fold in the rate of NO release (from
14 to 80 nmol/mL h) with the 4-fold increase in GSNO concentration (from 0.5
to 2.0 mM) reflects a restriction imposed by the viscous HPMC matrix on the
diffusion of the GSNO molecules; thus, reducing the frequency of effective
collisions that lead to NO production (based on reaction 1). This effect may
underlie the slow release of NO from the HMPC/GSNO formulations that, in
turn, is critical for obtaining therapeutic actions of NO during topical
applications. It has been shown previously that the topical application of
hydrogels containing GSNO was capable of promoting wound healing, leading to
higher rates of wound contraction and re-epithelization, lower levels of
inflammatory cells and an increase in collagen fiber density [18, 19, 34]. In these
cases, the maximum GSNO concentration used in the hydrogels was 200 mM,
which is 2.5-fold lower than the therapeutic GSNO concentration used in this
current study. Together with these results, the current data showing an absence of
therapeutic action of the 2.0 mM HPMC/GSNO formulation (with which the NO
release rate was 5.7-fold higher), suggest that GSNO concentrations for topical
therapeutic action in wound healing must remain in the micromolar range, most
likely below 500 mM. Above this concentration, one may expect cytotoxic NO
actions, although the threshold of cytotoxicity will necessarily depend on the type
of tissue and the environment in which NO is delivered.
The increase in collagen content during wound repair observed in this current
study may be attributed to an increase in collagen synthesis and/or proliferation of
fibroblasts [35, 36]. Consistent with other experimental studies [34, 37], our
results revealed an increase in HPMC/GSNO-mediated fibroblast proliferation,
based on Ki67 immunostaining, and an increase in collagen deposition (data not
shown) in the cheek pouches of hamsters subjected to oral mucositis.
It is well established that fibroblasts play a significant role in various stages of
the healing process. Following injury, fibroblasts migrate into the wound,
proliferate and produce matrix proteins (fibronectin, hyaluronic acid, collagen
and proteoglycans) [38]. In addition, under the influence of growth factors [39]
and mechanical stress [40], fibroblasts differentiate into myofibroblasts char-
acterized by the presence of stress fibers that contain a-smooth muscle actin [41].
In contrast, it has been reported that NO stimulates inflammatory cells to secrete a
greater level of growth factors including TGF-b [42], which is known to stimulate
myofibroblast differentiation. Ligands of the TGF-b superfamily bind to a type II
TGF-b receptor (TGF-b RII), a serine/threonine receptor kinase, and in turn
phosphorylate a type I TGF-b receptor [43]. Although there is a high affinity of
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type II receptors for TGF-b, their interaction is controlled by the availability of the
active form of TGF-b [44]. We observed a significant increase in TGF-b RII in the
group of hamsters subjected to 5-FU-induced oral mucositis and treated with
0.5 mM HPMC/GSNO compared with untreated animals. Denton et al.
demonstrated that TGF-b and its receptors are critical for the wound healing
process. Those authors showed that a lack of TGF-b RII in a transgenic mouse
resulted in impaired wound healing [45]. Thus, we speculate that the positive
effect of 0.5 mM HPMC/GSNO on mucosal wound healing observed in the
current study may be partially due to an upregulation of the TGF-b pathway
followed by an increase in myofibroblast differentiation, because myofibroblasts
robustly promotes wound closure [44]. Consistent with this hypothesis, our in
vitro studies showed a significant increase in the expression of Ki67 in
myofibroblasts incubated with GSNO (0.5 mM) compared with the untreated
cells.
Moreover, we demonstrated that 0.5 mM HPMC/GSNO significantly reduced
the 5-FU-induced increase in TNF-a levels and expression in cheek pouch tissues
on day 14. In contrast, we did not observe any significant differences in IL-1b
levels or expression in cheek pouch tissue between groups subjected to 5-FU-
induced oral mucositis. It is well established that cytokines, in particular TNF-a
and IL-1 b, play important roles in the pathophysiology of oral mucositis [4, 30].
The literature indicates that inflammatory cytokines stimulate iNOS-derived NO
production and that NO mediates cytokine cytotoxicity and inflammatory events
[46]. Consistent with these findings, we detected a significant increase in
immunostaining for iNOS in the inflamed connective tissue of hamster cheek
pouches on the 14th day of the 5-FU-induced oral mucositis when compared with
the Healthy group. The topical application of 0.5 and 2.0 mM HPMC/GSNO
inhibited iNOS expression indicating that GSNO potentially protects against
chemotherapy-induced iNOS activation in oral mucositis [37, 47]. Consistent
with our data, it has been shown that GSNO, by reducing iNOS, reduces TNF-a
expression in a rat model of focal cerebral ischemia [48] and in experimental
periodontal disease in rats [49]. The negative modulation of iNOS by GSNO may
underlie these findings. Indeed, it is well established that NO, whether released
from exogenous donors or generated enzymatically, can inhibit the expression and
activity of iNOS [50].
In this study, the topical administration of HPMC/GSNO formulations to
hamsters subjected to 5-FU-induced oral mucositis provided evidence that apart
from its effect on proliferation, 0.5 mM HPMC/GSNO significantly decreased
TUNEL-positive cells in cheek pouch tissue when compared with the Saline group
suggesting an inhibitory effect on 5-FU-induced cell death. Cell death is
considered an important component of chemotherapy-induced mucosal injury
[5]. Both chemo- and radiotherapy damage the mucosal lining and induce
apoptosis [5, 51]. However, the mechanism by which GSNO decrease TUNEL-
positive cells requires further investigation.
An important aspect of this current study is the identification of period-
ontopathogens in the context of oral mucositis. Mucositis ulcers are deep and are
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colonized quickly by oral bacteria [5]. In animal models, the number of mucosal
bacteria increases by over 300-fold during the transition from intact to ulcerated
epithelium [5] suggesting that ulcerated mucosa is a desirable colonization site. In
addition, individuals with periodontitis that present a more complex microbiota
show a higher risk of developing oral mucositis, which reinforces the relevance of
studying the role of bacteria in the pathophysiology of oral mucositis [7]. Thus,
the current investigation analyzed the mean frequency of detection and the levels
of oral periodontopathogens in samples collected from cheek pouches of animals
subjected to 5-FU-induced mucositis and from healthy hamsters.
In this study, increases in Gram-negative bacteria were observed in animals
subjected to oral mucositis compared with healthy animals. Consistent with these
results, Wang et al. reported that chemotherapy favors the growth of Gram-
negative anaerobic bacteria with virulent phenotypes, leading to a cascade of
inflammatory events and triggering oral mucositis [52]. We also observed that the
topical application of 0.5 mM HPMC/GSNO greatly reduced the levels of several
periodontopathogens including P. gingivalis and T. forsythia. This finding is very
relevant given that P. gingivalis is considered one of the main pathogens in the oral
cavity because it is resistant to nitrosative stress [53, 54]. Furthermore, it has been
shown that P. gingivalis and associated secreted products inhibit the migration of
oral epithelial cells in vitro [55] suggesting their involvement in delayed wound
healing.
Conclusions
In this investigation, we demonstrated that 0.5 mM HPMC/GSNO accelerated the
healing of lesions induced by 5-FU in the oral mucosa of hamsters on day 14,
most likely due to its anti-inflammatory, antimicrobial, anti-apoptotic and
proliferative effects.
Supporting Information
File S1. Figure S1, Real-time NO release profile of the 2.0 mM HPMC/GSNO
formulation measured by chemiluminescence at 37 C˚. Inset: Integrated NO signal
extracted from the kinetic curve, showing the total NO released from the
formulation over the same time-scale. The straight lines show the linear regression
of the experimental data and the calculated rates of NO release for two sections of
the curve. Figure S2, The cheek pouches of animals subjected to 5-FU-induced
oral mucositis showed a significant increase (P,0.05) of neutrophils on day 14
when compared with the Healthy and Mechanical Trauma (MT) control groups.
0.5 mM HPMC/GSNO treatment substantially (P,0.05) reduced the number of
neutrophils in cheek pouch tissue compared with both the HPMC and Saline
groups. Bars denote the means ¡ standard errors of the number of neutrophils
from at six slides per group (6 animals per group). *denotes a significant
difference (P,0.05) compared with the Healthy group; **denotes a significant
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difference (P,0.05) compared with the MT group, +denotes a significant
difference (P,0.05) compared with the Saline group; #denotes a significant
difference (P,0.05) compared with the HPMC group. Data were analyzed using
the Kruskal Wallis and Mann Whitney tests.
doi:10.1371/journal.pone.0113378.s001 (DOC)
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